Vision

People with congenital stationary night blindness (CSNB) are unable to distinguish objects in dim-light conditions. This impairment presents challenges, especially where artificial lighting is unavailable or when driving at night. Read More

For up to 3 million Americans each year, what was supposed to be a fun day at the ski slopes, at a playground or on a football field quickly takes a turn for the worse. While simple steps – such as wearing a helmet – can prevent serious head injury resulting from a sudden high-impact fall or a blow to the head, those measures are less effective at preventing concussions. Read More

A novel computational platform developed by researchers from the University of Pittsburgh School of Medicine identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision. Read More

Allison Proffitt, for Bio-IT World, recently reported how innovative vision restoration/care and video gaming have merged.  Her article features her conversation with Edouard Gasser, CEO of Tilak, who speaks of his partnership with McGowan Institute for Regenerative Medicine affiliated faculty member José-Alain Sahel, MD, Chair and Distinguished Professor of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, director of the UPMC Eye Center, and the Eye and Ear Foundation Endowed Chair of Ophthalmology. Read More

For centuries, people thought that blindness was incurable – once the darkness sets in, it never retreats. Unlike in fish and frogs, the human retina doesn’t regenerate, and the vision loss caused by damage to cells in the back of the eye – be it genetic or physical – can rarely be fixed. But new research suggests that regrowing the retina may not be science fiction after all. Read More

After 40 years of blindness, a 58-year-old man can once again see images and moving objects, thanks to an injection of light-sensitive proteins into his retina. Read More

The Henry L. Hillman Foundation recently announced a $25 million gift to the University of Pittsburgh.  In all, $20 million of the gift will fund vision care research and development through The Eye & Ear Foundation, which supports Pitt’s Departments of Ophthalmology and Otolaryngology by advancing leading-edge academics and research to enhance patient care. As a result of the gift, The Eye & Ear Foundation has passed the halfway point in its campaign to support vision restoration breakthroughs, advance technologies and therapies addressing vision loss, lower barriers to healthcare for all Pittsburghers, and fuel the growth of the city’s burgeoning biotech sector.  The gift will, among other efforts, improve access to vision care for underserved communities through outreach and direct care; help build and staff a vision “street lab” to test new treatments and therapies in safe, controlled, virtual and real-life environments; and support research into breakthrough programs such as biomedical solutions to corneal blindness. The gift will also fund commercialization efforts and will, in turn, create job and training opportunities for adjacent neighborhoods and the city with an emphasis on promoting equitable access to services and employment. Read More

The University of Pittsburgh announced a collaboration with the U.S. Food and Drug Administration’s Center for Devices and Radiological Health to help address the needs of the visually impaired through the expertise, facilities, and research of the world-class University of Pittsburgh School of Medicine’s Department of Ophthalmology. Read More

Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of patients have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. The estimated incidence of LHON is approximately 800-1,200 new patients who lose their sight every year in the United States and the European Union. Read More

McGowan Institute for Regenerative Medicine affiliated faculty member Jason Shoemaker, PhD, Assistant Professor in the Departments of Chemical and Petroleum Engineering and Computational and Systems Biology, recently received National Institutes of Health funding for two R21s. Both of these R21s will be awarded from the National Institute of Allergy and Infectious Diseases. Read More

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa (RP), the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.  McGowan Institute for Regenerative Medicine affiliated faculty member José-Alain Sahel, MD, Chair of the Department of Ophthalmology at the University of Pittsburgh School of Read More

Diabetic patients monitor their blood glucose throughout the day, watching for peaks and valleys. Just taking a sample once during a visit to the doctor’s office would not give a clear picture of whether the patient’s diabetes is under control. The same is true of glaucoma patients, whose intraocular pressure (IOP), or pressure within the eye, is too high. Read More

Chartwell Pennsylvania, LP, a provider of home infusion, specialty pharmacy, and enteral nutrition, recently became the first provider to administer TEPEZZA (teprotumumab-trbw) in a home-infusion setting. Approved on January 21, 2020, TEPEZZA is the first and only FDA-approved medicine for the treatment of thyroid eye disease (TED), a rare and serious autoimmune disease. Home infusion therapy continues to ease the burden of care placed on hospitals and other health care facilities throughout the COVID-19 outbreak. Read More

The mission of the UPMC Eye Center is to improve quality of life through the preservation and restoration of vision.  The UPMC Eye Center is focused to: Read More

Elaine Vitone, PittMed, recently visited with McGowan Institute for Regenerative Medicine affiliated faculty member Ian Sigal, PhD, Assistant Professor and the founding Director of the Laboratory of Ocular Biomechanics in the University of Pittsburgh Department of Ophthalmology.  There she learned about Dr. Sigal’s work and shared her experience in her article (with video), “The Forest, the Trees, and the Leaves.” Read More

UPMC has implanted the first patient in the United States with a new wireless retinal device as part of a clinical trial aimed at restoring partial sight to patients with advanced age-related macular degeneration (AMD), a disease that leads to permanent blindness. Read More

It is with sadness that the McGowan Institute for Regenerative Medicine announces the passing of affiliated faculty member James Funderburgh, PhD. Read More

In her article, Elaine Vitone, a writer for PittMed, recently laid out the extraordinary activity arising in Pittsburgh in UPMC’s planned vision and rehabilitation hospital in Uptown, near the UPMC Mercy hospital. The nine-story, 410,000 square-foot facility, which was painstakingly designed to spec with both patients and scientists in mind, will be ready for the entire Ophthalmology Department in 2022. Read More

The University of Pittsburgh received a $6 million grant from the Richard King Mellon Foundation to support the development of a cortical vision research program in the Pitt School of Medicine Department of Ophthalmology. The program will aim to understand how the eye and the brain work together to help us see the world and use that knowledge to develop new ways to restore vision using various technologies such as brain computer interfaces and novel genetic technologies. Read More

Self-driving cars rely on their ability to accurately “see” the road ahead and make adjustments based on what they see. They need to, for instance, react to a pedestrian who steps out from between parked cars, or know to not turn down a road that is unexpectedly closed for construction. As such technology becomes more ubiquitous, there’s a growing need for a better, more efficient way for machines to process visual information. Read More

Promising first results from the clinical feasibility trial of PRIMA, a wireless retinal implant designed to help restore useful vision in patients with advanced atrophic dry age-related macular degeneration (AMD), were presented recently at the American Academy of Ophthalmology 2018 annual meeting held in Chicago. The presentation was acknowledged as the “Best Paper” of Retina Session II at the meeting. Read More

McGowan Institute for Regenerative Medicine affiliated faculty member Jenny Yu, MD, Vice Chair of Clinical Operations for the Department of Ophthalmology, UPMC Eye Center, a member on the Orbital, Oculoplastic, and Aesthetic Surgery Service, and an Assistant Professor of Ophthalmology and Otolaryngology, University of Pittsburgh, is a co-founder of Project Theia along with Katie Duncan, MD, MDEyecare LLC.  Founded in 2017, Project Theia is a non-profit organization named after the Greek goddess of sight and heavenly light and is focused on Read More

In the Pitt Summer 2018 edition, author Jennie Dorris highlights the career paths of McGowan Institute for Regenerative Medicine affiliated faculty member James Funderburgh, PhD, Professor of Ophthalmology and Cell Biology & Physiology, University of Pittsburgh School of Medicine, and his wife, Martha Funderburgh, MPH, Lab Manager and Sr. Research Technician, Corneal Cell Biology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine.  The story provides “an exciting outlook for a research team inspired by personal experience and driven by the desire to help others see a brighter future.” Read More

In the world of ophthalmology, researchers have always made vision restoration by retinal repair their goal. Today, this goal is more obtainable than ever through modern technologies and medical practices, and the first successful procedures have already taken place. Read More

If you want to take clear photographs, you don’t use sandpaper to clear a smudge from your camera’s lens. Similarly, if you want to see clearly, the lens of your eye has to be free of obstruction. Read More

As reported by Madison Brunner for Inside UPMC, inherited retinal degeneration affects about one out of every 2,000 people worldwide and severely impacts quality of life. Due to mutated genes, this disorder causes blindness and currently has no treatment. Read More

Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation
Michelle L. Ratay, Elena Bellotti, Riccardo Gottardi, and Steven R. Little
Advanced Healthcare Materials; 2017 Dec;6(23). Read More

We are pleased to announce the establishment of an interdisciplinary research program in the science of eye transplantation. This unique program in the science of eye transplantation is a joint effort between the Department of Ophthalmology and the Department of Plastic Surgery, and is led by McGowan Institute affiliated faculty member Kia Washington, MD, the director, in coordination with Dr. Sahel.  In addition to leveraging the skills and expertise of members of the Departments of Ophthalmology and Plastic Surgery, this innovative program will also include experts in immunology, transplant surgery, the neurosciences, and other related disciplines. Read More

The University of Pittsburgh School of Medicine has entered into an agreement with three world-renowned French research institutions—the University Pierre et Marie Curie of the Sorbonne Universités in Paris, the Institut National de la Santé et de la Recherche Médicale (Inserm), and the Centre National de la Recherche Scientifique (CNRS)—to focus on collaborative research and education in the fields of medicine and biomedical sciences. Read More

The University of Pittsburgh Innovation Institute has awarded funding to four University of Pittsburgh Innovator teams to help them move their discoveries towards commercialization, where they can make a positive impact on society.  The teams were selected by a panel of judges from a pool of two dozen applicants that was narrowed into a group of 10 finalists. Two of the recognized teams include affiliated faculty leadership from the McGowan Institute for Regenerative Medicine. Read More

One of the world’s top experts in retinal diseases, who is developing an artificial retina as well as other regenerative therapies to treat blindness and vision impairments, has been named as the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, director of the UPMC Eye Center, and the Eye and Ear Foundation Chair of Ophthalmology. Read More

The Neural Devices Engineering Laboratory, Institute for Complex Engineered Systems at Carnegie Mellon University, is headed by Senior Systems Scientist Shawn Kelly, PhD, a McGowan Institute for Regenerative Medicine affiliated faculty member.  At the Neural Devices Engineering Laboratory, Dr. Kelly and his team design and develop novel medical technologies, in particular circuits for neural interfaces. The team primarily designs neural stimulation circuits and inductively-coupled wireless power and data telemetry systems. They also study electrode-tissue interface, as well as the process for inducing nerves to fire, in order to develop optimized, longer-lasting neural interfaces for neural stimulation and recording applications and neuroscience research. Read More

Corneal blindness affects millions worldwide. To date, the only treatment available is a corneal transplant. But potential new cures are coming from unexpected places—including wisdom teeth! Read More

The University of Pittsburgh’s Center for Medical Innovation (CMI) awarded grants totaling $85,000 to four research groups through its 2015 Round-2 Pilot Funding Program for Early Stage Medical Technology Research and Development. Two of these funding proposals from McGowan Institute for Regenerative Medicine affiliated faculty members are for a nanowire glaucoma drainage implant and for bioactive hydrogels for bone regeneration.  Details include: Read More

As reported by Heather Chronis in the Fall 2015 Sight & Sound newsletter of the Eye and Ear Foundation of Pittsburgh, the Ophthalmology and Visual Sciences Research Center at the University of Pittsburgh, under the direction of McGowan Institute for Regenerative Medicine affiliated faculty member Robert Hendricks, PhD, Joseph F. Novak Professor and Vice-Chair for Research in the Department of Ophthalmology at the University of Pittsburgh School of Medicine, has been the recipient of multiple restricted and unrestricted grants from the Research to Prevent Blindness (RPB). Founded in 1960 by Dr. Jules Stein, RPB is a national leader in the effort to fund, coordinate, and promote vision research in the United States. From its infancy to today, RPB has advocated at all levels for vision research. RPB restricted and unrestricted grants have helped to launch the careers of countless vision scientists. Read More

As reported by Carrie Fogel in the Fall 2015 Sight & Sound newsletter of the Eye and Ear Foundation of Pittsburgh, while most people anticipate the summer season as a time for vacations and time away from work, that was not the case for McGowan Institute for Regenerative Medicine affiliated faculty member Jeffrey Gross, PhD, the new Director of the Louis J. Fox Center for Vision Restoration. Dr. Gross arrived in Pittsburgh in late July; a time when many were spending their days on sunny beaches, Dr. Gross was already hard at work setting up his new laboratory in the University of Pittsburgh’s Biomedical Science Tower.  Dr. Gross’ research is now conducted at the Charles and Louella Snyder Laboratory for Retinal Regeneration and focuses on ocular development, disease, and regeneration. Read More

As reported by Carrie Fogel in the Fall 2015 Sight & Sound newsletter of the Eye and Ear Foundation of Pittsburgh, the Louis J. Fox Center for Vision Restoration is well known for engaging scientists of various backgrounds. Such collaborations help to ensure the success of vision restoration, which is the goal of the unique Ocular Tissue Engineering and Regenerative Ophthalmology (OTERO) Fellowship that is offered each year. Fellows, with backgrounds other than ophthalmology, are tasked with using a multi-disciplinary approach to pursue a ‘revolutionary’ idea that, if successful, will provide radical improvement in the treatment or prevention of vision impairment. One former OTERO fellow and currently an Assistant Professor of Chemical and Petroleum Engineering and of Ophthalmology, Morgan Fedorchak, PhD (pictured), who has a PhD in Bioengineering from the University of Pittsburgh, had one such revolutionary idea; one that is generating excitement and anticipation from scientists, physicians, and patients alike. Read More

As reported by Mark Roth, Pittsburgh Post-Gazette, McGowan Institute for Regenerative Medicine deputy director Vijay Gorantla, MD, PhD, associate professor of surgery in the Department of Plastic Surgery at the University of Pittsburgh, the administrative medical director of the Pittsburgh Reconstructive Transplant Program at UPMC, and a clinician who has helped pioneer Pitt’s hand and arm transplants, is the first to acknowledge that it will be years before surgeons can attempt whole eye transplants in human patients. But he says the approach has a key advantage over other attempts to repair traumatic injuries to the eye, whether they have come from a roadside bomb, an industrial accident, or a car collision. The eye is so complex that trying to repair its internal parts is an enormous challenge. Read More

“It looks like if you push cells to a certain stage,” Dr. Nasonkin said, “they can self-assemble as long as you feed them the right nutrition.” And that means scientists may soon be able to create a complete “retinal patch” for people with retinitis pigmentosa or other diseases. Read More

As reported by Heather Chronis in the Fall 2015 Sight & Sound newsletter of the Eye and Ear Foundation of Pittsburgh, McGowan Institute for Regenerative Medicine affiliated faculty member Barry Hirsch, MD, Director of the Division of Otology in the Department of Otolaryngology in the University of Pittsburgh School of Medicine, is highly regarded by his patients as compassionate and knowledgeable, and is nationally recognized for excellence in ear surgery. He came to the University of Pittsburgh in 1979 for a residency in Otolaryngology (ENT), after graduating from the University of Pennsylvania Medical School. His interview with the Chairman of the Department of Otolaryngology, Eugene N. Myers, MD, sealed the deal for relocating to Pittsburgh. Read More